CLChin-Chan Lee

Chin-Chan Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chin-Chan Lee has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Chi-Chin Sun

    Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan

    1 shared publication
  • Chiao‐Yin Sun

    Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan

    1 shared publication
  • Chi‐Chin Sun

    Community Medicine Research Center, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan

    1 shared publication
  • Chun-Fu Liu

    Department of Ophthalmology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan

    1 shared publication
  • Heng‐Chih Pan

    Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan

    1 shared publication
  • I-Wen Wu

    College of Medicine, Chang Gung University, Taoyuan, Taiwan

    1 shared publication

Latest Publications

  • Open Access

    Associations of Three-Dimensional Anthropometric Body Surface Scanning Measurements and Coronary Artery Disease

    by Ning-I Yang, Li-Tang Kuo, Chin-Chan Lee, Ming-Kuo Ting, I-Wen Wu, Shuo-Wei Chen, Kuang-Hung Hsu

    Background and Objectives: The relationship between three-dimensional (3D) scanning-derived body surface measurements and biomarkers in patients with coronary artery disease (CAD) were assessed. Methods and Methods: The recruitment of 98 patients with CAD confirmed by cardiac catheterization and 98 non-CAD patients were performed between March 2016 and December 2017. A health questionnaire on basic information, life style variables, and past medical and family history was completed. 3D body surface measurements and biomarkers were obtained. Differences between the two groups were assessed and multivariable analysis performed. Results: It was found that chest width (odds ratio [OR] 0.761, 95% confidence interval [CI] = 0.586–0.987, p = 0.0399), right arm length (OR 0.743, 95% CI = 0.632–0.875, p = 0.0004), waist circumference (OR 1.119, 95% CI = 1.035–1.21, p = 0.0048), leptin (OR 1.443, 95% CI = 1.184–1.76, p = 0.0003), adiponectin (OR 0.978, 95% CI = 0.963–0.994, p = 0.006), and interleukin 6 (OR 1.181, 95% CI = 1.021–1.366, p = 0.0254) were significantly associated with CAD. The combination of biomarker scores and body measurement scores had the greatest area under the curve and best association with CAD (area under the curve of 0.8049 and 95% CI = 0.7440–0.8657). Conclusions: Our study suggests that 3D derived body surface measurements in combination with leptin, adiponectin, and interleukin 6 levels may direct us to those at risk of CAD, allowing a non-invasive approach to identifying high-risk patients.


  • Open Access

    Accelerated Peripapillary Retinal Nerve Fiber Layer Degeneration in Patients With Chronic Kidney Disease: A 2-Year Longitudinal Study

    by Ling Yeung, I-Wen Wu, Chun-Fu Liu, Yu-Tze Lin, Chin-Chan Lee, Chi-Chin Sun

    Purpose: To evaluate the longitudinal changes in the peripapillary retinal nerve fiber layer (pRNFL) in patients with chronic kidney disease (CKD). Methods: In this prospective cohort study, the CKD group consisted of patients with CKD stage ≥ 3. Age-matched healthy controls were enrolled at a 1:4 ratio. Spectral-domain optical coherence tomography was used to measure the pRNFL at baseline, 1 year, and 2 years. Within-group longitudinal changes and between-group comparisons were performed using linear mixed models. Results: Overall, 152 patients with CKD and 40 controls were included (mean ages, 62.8 ± 9.1 years vs. 63.0 ± 9.3 years; P = 0.931). The CKD group showed faster loss of pRNFL than the control group (−0.87 µm/y vs. −0.26 µm/y; P = 0.004). Subgroup analysis found that the rate of pRNFL change was −0.41 µm/y in stage 3a CKD, −0.74 µm/y in stage 3b, −0.98 µm/y in stage 4/5, and −1.38 µm/y in end-stage renal disease. Multiple linear regression analysis revealed that CKD stage (coefficient = −0.549; 95% confidence interval [CI], −0.966 to −0.131; P = 0.010), hypertension (coefficient = −1.557; 95% CI −3.013 to −0.101; P = 0.036), and rim area (coefficient = −1.505; 95% CI, −2.940 to −0.070; P = 0.040) were factors associated with the pRNFL change over 2 years. Conclusions: Patients with CKD experienced faster pRNFL loss than healthy controls did. Severity of CKD, hypertension, and rim area were independent factors associated with the loss of pRNFL. Translational Relevance: This study contributes to our understanding of retinal neurodegeneration in normal aging and in patients with chronic kidney diseases.


  • Open Access

    Higher risk of malignant neoplasms in young adults with end‐stage renal disease receiving haemodialysis: A nationwide population‐based study

    by Heng‐Chih Pan, Chiao‐Yin Sun, I‐Wen Wu, Tien‐Ling Tsai, Chi‐Chin Sun, Chin‐Chan Lee

    Aim: Previous investigations have shown that end‐stage renal disease (ESRD) is associated with an increased risk of malignancies. The aim of this study was to explore the association between ESRD in patients undergoing maintenance haemodialysis (HD) and the incidence of malignancies according to age.Methods: We analysed a nationwide cohort retrieved from Taiwan's National Health Insurance Research Database to study the incidence of malignancies in patients who were and were not receiving HD. One million beneficiaries were randomly selected and followed from 2005 to 2013. Of these 1 000 000 patients, 3055 developed ESRD and commenced maintenance HD during this period. For each HD patient, four age‐, gender‐ and diabetes‐matched controls were selected from the database (n = 12 220). We further stratified the patients according to age. The study endpoint was the occurrence of malignancy.Results: The incidence rates of malignancy were 6.8% and 4.9% in the HD and control groups, respectively. Competing risk regression analysis indicated that age, HD, male gender and diabetes were associated with an increased risk of malignancy. When further stratified according to age, the odds ratios of developing cancer were 5.8, 1.9, 1.9 and 1.5 among the HD patients aged <40 years, 40–49 years, 50–59 years and 60–69 years, respectively.Conclusion: The patients with ESRD who received HD had a significantly higher cumulative risk of malignancy, especially those with a young age. Therefore, specialized cancer screening protocols for young HD patients might help to prolong their lifespan.